-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-519994-20-00
5
Agitation Associated with Alzheimer’s Disease
-
2025-520554-11-00
5
Cardiovascular Disease
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2024-517337-41-00
5
2026-05-12
Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2024-520444-42-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2024-520445-23-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca